WebMar 7, 2008 · We show that ATR is specifically activated during cisplatin treatment and co-localizes with H2AX, forming nuclear foci at the site of DNA damage. Blockade of ATR with a dominant-negative mutant inhibits cisplatin … WebE4F1-depletion impacts on ATM/ATR-CHK1 signaling in response to CT drugs Gemcitabine and Cisplatin. (A)—ShRNA-mediated depletion of E4F1 in SUM159 TNBC cells impacts on CHK1 protein level and on the S 345 phosphorylation of CHK1 by ATM/ATR in response to Gemcitabine and Cisplatin. This effect was reversed by the co-expression of the shRNA ...
The identification of the ATR inhibitor VE-822 as a therapeutic ...
WebNov 14, 2024 · ( D) Assessment of cisplatin sensitivity in KP and RP cell lines. RP GI 50 = 14.3 µMol; KP GI 50 = 29.1 µMol. ( E) RP cell lines were significantly (p < 0.0001) more sensitive to ATR inhibition... WebJul 1, 2024 · Cisplatin first activates ATR kinase [69] which then activates p53 by phosphorylating at serine-15 [70]. p53 activates p21, Mdm2 and GADD45 genes which are responsible for cell cycle arrest and lead to apoptosis through DNA repair pathway [44]. p53 causes apoptosis directly by different mechanisms like: Degradation of FLIP (flice-like ... clumping with anti a
Cisplatin - an overview ScienceDirect Topics
WebThe effect of compounds 3a–d on the ATR-dependent phosphorylation of Chk1 was evaluated by western immunoblotting, as previously published . Briefly, MCF7 cells were pretreated with 1 µM of the compounds for 30 min and exposed to 10 µM cisplatin in the presence or absence of the compounds for 8 h to induce DDR. WebJan 12, 2016 · These results indicate that inhibiting ATR-Chk1 activation with WYC0209 suppresses p-glycoprotein expression and increases cisplatin activity in bladder cancer. Our findings collectively suggest that ATR-Chk1 is a target for improving the efficacy of cisplatin in bladder cancer. Keywords: ATR-Chk1; bladder cancer; natural products. WebAug 1, 2024 · Blocking this novel pathway by inhibiting ROS, DUOXA1, ATR or Chk1 effectively overcomes cisplatin resistance in vitro and in vivo. Significantly, the clinical studies also confirm the activation of ATR and DOUXA1 in ovarian cancer patients, and elevated DOUXA1 or ATR-Chk1 pathway correlates with poor prognosis. clumpong after sleeoing bag washing